This website uses cookies to provide you with the best possible user experience. We log, strictly anonymously, your user behaviour in order to identify important topics for visitors and to detect any malfunctions that may occur. For more information and to opt out of tracking, please see our Privacy Policy.

Successful market access for gene therapies

Kuhn, A., Mrosowsky, T., Schönermark, M.P. (2018): 

White Paper. 


Gene therapies promise to permanently improve and even cure serious disorders, that, in the past, were considered to be irremediable. This is an enormous advancement for the affected patients in terms of their living conditions. Nevertheless, it's a long and windy road from the first research up until a successful market readiness has been achieved.

Dr. Alexandra Kuhn, Thora Mrosowsky and Prof. Matthias P. Schönermark M.D., Ph. D. examined the strategic challenges and best practices for a successful market access for gene therapies and summarized their work in an extensive white paper.

A profound analysis of the current regulatory framework for gene therapies in the USA and Europe addresses existing requirements as well as potential chances and risks. A comprehensive precedence analysis gives an overview of underlying evidences and the current reimbursement of gene therapies that are already on the market. Since the new paradigm of gene therapies brings along several uncertainties, including a sufficient reimbursement mode, possible reimbursement models are discussed in the white paper, and recommendations for a successful market access are outlined.

Exclusive download white paper

We would be pleased to provide you with the white paper free of charge. Please send us your contact details using the form provided.

Successful market access for gene therapies
Strategic challenges and possible solutions
to the top